News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Femta Pharmaceuticals and Lonza Group Ltd. (LZAGY.PK) Enter into Manufacturing Services Agreement and License for Lonza's GS Gene Expression System(TM)



12/15/2009 8:54:03 AM

SAN DIEGO & BASEL, Switzerland--(BUSINESS WIRE)--Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis. The agreement allows Femta access to Lonza’s GS Gene Expression System™ (GS: glutamine synthetase) along with cell line, purification and process development to support a robust cGMP process for Femta’s clinical development program.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES